文献速递艾滋病与性传播感染

HIV-1 治疗中断期间病毒反弹预测标志物及血液与脑脊液安全性评估

Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究纳入 11 例 HIV-1 阳性者,在分析性治疗中断(ATI)的四个时间点采集 PBMC、血浆和脑脊液,评估 ATI 安全性并寻找预测病毒反弹的标志物。结果显示 ATI 未增加病毒储存库大小,未见神经元损伤或炎症迹象;SLFN11、APOBEC3G 及 Tat-Rev 转录本在病毒反弹前升高,可能作为预测标志物。

要点

  • ATI 未增加 HIV-1 DNA 储存库,脑脊液 NFL、YKL-40 及免疫激活标志物无升高。
  • SLFN11 和 APOBEC3G 在 ATI 后、病毒反弹前表达升高。
  • Tat-Rev 转录本在中断后病毒反弹前升高,或可预测反弹。

核心结论

  • 在严密监测下,分析性治疗中断未增加病毒储存库大小,也未出现神经元损伤或炎症迹象,提示此类 ATI 是安全的。
  • SLFN11、APOBEC3G 表达升高及 Tat-Rev 转录本增加出现在病毒反弹之前,可能作为预测病毒反弹的潜在生物标志物。

研究设计与样本

  • 研究纳入 11 例 HIV-1 阳性个体,在 ATI 期间四个不同时间点采集 PBMC、血浆和脑脊液(NCT02641756)。
  • 采用 PCR 方法检测总 HIV-1 DNA、整合 HIV-1 DNA、细胞相关 HIV-1 RNA 转录本及限制因子表达。
  • 在脑脊液中检测神经炎症和神经元损伤标志物 NFL 与 YKL-40,并在血浆和脑脊液中检测 neopterin、色氨酸和犬尿氨酸作为免疫激活标志物。

主要发现

  • 总 HIV-1 DNA、整合 HIV-1 DNA 及细胞相关病毒 RNA 转录本在 ATI 前后无差异。
  • 基线至病毒反弹期间,脑脊液 NFL 或 YKL-40 未见显著升高。
  • ATI 期间免疫激活标志物未升高。
  • ATI 后、病毒反弹前,限制因子 SLFN11 和 APOBEC3G 表达升高。
  • 中断后病毒反弹前,Tat-Rev 转录本升高。

临床怎么用

  • 在严密监测条件下,ATI 未显示增加病毒储存库或神经炎症/损伤迹象,可为 HIV-1 治愈策略研究中的 ATI 安全性提供参考。
  • SLFN11、APOBEC3G 及 Tat-Rev 转录本可能作为预测病毒反弹的候选标志物,但需进一步验证。

局限性

  • 研究样本量较小(11 例),结论需在更大队列中验证。
  • 预测标志物与病毒反弹的关联为观察性发现,尚未建立临床可用的预测阈值或验证模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants. Little is known about the safety of ATI and its long-term impact on patient health. OBJECTIVES: ATI safety was assessed and potential biomarkers predicting viral rebound were evaluated. METHODS: PBMCs, plasma and CSF were collected from 11 HIV-1-positive individuals at four different timepoints during ATI (NCT02641756). Total and integrated HIV-1 DNA, cell-associated (CA) HIV-1 RNA transcripts and restriction factor (RF) expression were measured by PCR-based assays. Markers of neuroinflammation and neuronal injury [neurofilament light chain (NFL) and YKL-40 protein] were measured in CSF. Additionally, neopterin, tryptophan and kynurenine were measured, both in plasma and CSF, as markers of immune activation. RESULTS: Total HIV-1 DNA, integrated HIV-1 DNA and CA viral RNA transcripts did not differ pre- and post-ATI. Similarly, no significant NFL or YKL-40 increases in CSF were observed between baseline and viral rebound. Furthermore, markers of immune activation did not increase during ATI. Interestingly, the RFs SLFN11 and APOBEC3G increased after ATI before viral rebound. Similarly, Tat-Rev transcripts were increased preceding viral rebound after interruption. CONCLUSIONS: ATI did not increase viral reservoir size and it did not reveal signs of increased neuronal injury or inflammation, suggesting that these well-monitored ATIs are safe. Elevation of Tat-Rev transcription and induced expression of the RFs SLFN11 and APOBEC3G after ATI, prior to viral rebound, indicates that these factors could be used as potential biomarkers predicting viral rebound.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. De Scheerder MA, Van Hecke C, Zetterberg H, et al. Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. J Antimicrob Chemother. 2020. PMID: 32053203. doi:10.1093/jac/dkaa003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。